Prof. dr. rudolf prager - publikationen

Univ.-Prof. Dr. Rudolf Prager
Literaturliste
Original- und Übersichtsarbeiten:
Punzengruber C, Prager R, Kolassa N, Winkler F, Suko J : Calcium gradient dependent and calcium gradient independent phosphorylation of sarcoplasmic reticulum by orthophosphate . The role of magnesium .Eur. J. Biochem. 92, 349 - 359, 1978. Prager R, Punzengruber C, Kolassa N, Winkler F, Suko J : Ionized and bound calcium inside isolated sarcoplasmic reticulum of skeletal muscle and its significance in phosphorylation of adenosine triphosphatase by orthophosphate. Eur. J. Biochem. 97, 239 - 250, 1979. Schernthaner G, Müller MM, Prager R, Mühlhauser I : Die klinische Bedeutung des Glycohämoglobins ( HbA1 ). Wien. klin. Wschr. 92, 1-11, 1980. Prager R, Schernthaner G, Müller MM : HDL - Cholesterin und Diabetes mellitus. Analyse von Diabetestyp, Therapieform, Diabetesdauer und Stoffwechselkontrolle. Wien. klin. Wschr. 92, 672 - 677, 1980. Kuzmits R, Schernthaner G, Mühlhauser I, Prager R, Müller MM : Metabolismus der Schilddrüsenhormone und diabetische Stoffwechselkontrolle. Bulletin S.S.C.C./ S.G.K.C. 21, 170- 178, 1980. Prager R, Schernthaner G, Mühlhauser I, Müller MM . Einfluss von Diabetestyp, Stoffwechselkontrolle ( HbA1 ), Therapieform und Diabetesdauer auf HDL - Cholesterin und Plasmalipide bei Typ - I und Typ - II Diabetes mellitus. Verh. Dt. Ges. Inn. Med. 86, 991 - 994, 1980. Prager R, Schernthaner G, Meisinger V, Mühlhauser I, Müller MM : Hypomagnesiämie - ein möglicher Angiopathierisikofaktor - und metabolischer Kontrollgrad bei Diabetes mellitus. Acta med. Austriaca 7, 203 - 204, 1980. Prager R, Schernthaner G, Kostner CM, Mühlhauser I, Dieplinger H, Lang PD : Plasmalipide, Lipoproteine, Apolipoproteine und LCAT bei Diabetes mellitus : eine Doppelblind Crossover Studie mit Bezafibrat. Verb.Dt.Ges.Inn.Med. 7, 992 - 995, 1981. Klein K, Sinzinger H, Schernthaner G, Silberbauer K, Prager R : Plättchensensitivitat fur Prostacyclin ( PG 12 ) bei Patienten mit juvenilem Diabetes mellitus. Wien. klin. Wschr. 93, 460 - 462, 1981. 10. Laggner P, Suko J, Punzengruber C, Prager R : Electron spin resonance studies on conformational changes of the sarcoplasmic reticulum Ca2 - ATPase induced by synergistic action of calcium and ATP. Zeitschr. f. Naturforschung 36b, 1136- 1143, 1981. 11. Prager R, Schernthaner G, Kostner GM, Mühlhauser I, Zechner R, Dorda W : Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins Al, All and B and LCAT activity in hyperlipidemic, non insulin dependent diabetics. Artherosclerosis 43, 321 - 327, 1982. 12. Prager R, Schernthaner G, Kostner G, Mühlhauser I, Meisinger V: Hypomagnesiämie bei Diabetes mellitus. Korrelationsanalysen mit Stoffwechselkontrollgrad, Lipidstatus und Thrombozytenfunktion. Akt. Endocrin. Stoffw. 3, 140 - 143, 1982. 13. Schernthaner G, Borkenstein M, Mathae R, Mayr WR, Hohenecker J, Prager R, Schober G, Susani M : Semisynthetisches und biosynthetisches Humaninsulin : Immunogenitätsuntersuchungen nach Langzeittherapie bei Typ - I Diabetikern und Bindungsanalysen an praformierten lgG Insulinantikörpern und Insulinrezeptoren.In "Neue Insuline :1.Internationales Symposion 1982 "Herausg. Petersen KG, Schluter KJ, Kerp L.: 140-148. 14. Prager R, Schernthaner G : Comparison of insulin receptor binding to monocytes and erythrocytes in newly diagnosed type II diabetes mellitus. Horm. metab. Res. 14, 561-563, 1982. 15. Luger A, Graf H, Prager R, Stummvoll HK : L’hemofiltration continue sur membrane de polysulfone. La Nouvelle Presse Medicale 11, 3657, 1982. 16. Prager R, Schernthaner G : Receptor binding properties of human insulin (recombinant DNA and human proinsulin and their interaction at the receptor site . Diabetes Care 5, Suppl. 104 - 106, 1982. 17. Stummvoll HK, Graf H, Ebm W, Luger A, Prager R, Wolf C : Allgemeine internistische Intensivmedizin - erste Erfahrungen an der neu eröffneten Intensivstation der ll. Medizinischen Universitätsklinik Wien. Acta med. Austriaca 9, 166-169, 1982. 18. Schernthaner G, Graninger W, Kwasny W, Prager R, Otto C : Diabetestherapie mittels kontinuierlicher Insulininfusion durch portale Pumpen : Metabolische Effekte der Kurzzeitbehandlung und Langzeitergebnisse bei Problempatienten . Acta. med. Austriaca 9, 205-213, 1982. 19. Graf H, Luger A, Prager R, Stummvoll HK : Stimulation of anti-glomerular basement membrane antibody production by plasma exchange in Good-pastures syndrome. In: 2nd Mitteleuropean Meeting on Nephrology Dialysis and Transplantation . Eds. : Barduagnis S, Pitzorno F, Rocco A . Wichtig Editore, Milano 257-259, 1982. 20. Graf H, Stummvoll HK, Luger A, Prager R: Effect of amino acid infusion on glomerular filtration rate. N. Engl. J. Med. 308, 159-160, 1993. 21. Prager R, Schernthaner G: Insulin binding of human and porcine monocomponent insulin to monocytes in type I ( insulin dependent ) diabetic patients and control subjects. Diabetologia 25, 235-237, 1983. 22. Prager R, Kovarik J, Schernthaner G, Woloszczuk W, Willvonseder R: Peripheral Insulin Resistance in Primary Hyperparathyreoidism. Grune & Stratton, Inc. 1983. 23. Kwasny W, Otto C, Prager R, Knoflach F, Schernthaner G: Kombinationstherapie von Insulin und Sulfonylharnstoff (HB 420) bei übergewichtigen, insulinresistenten Typ II-Diabetikern: Analyse von Insulinrezeptorbindung, Insulinsekretion und Stoffwechselkontrollgrad. Kombinationstherapie Insulin/Sulfonylharnstoff, Karger, Basel 1983. Hrsg. W.Bachmann und H.Mehnert (München). 24. Schernthaner G, Kovark J, Prager R, Willvonseder R: Growth Hormone, prolactin and insulin following arginine infusion in primary hyperparathyreoidism before and after parathyeroidectomy. Acta Endocrinologica 104, 206-209, 1983. 25. Stummvoll HK, Graf H, Luger A, Prager R: Spontaneous arteriovenous plasma separation. Critical Care Medicine 10, 1983. 26. Graninger W, Prager R, Schernthaner G: Einfluss der kontinuierlichen Insulininfusion mittels tragbarer, programmierbarer Insulinpumpen auf das Insulinrezeptorverhalten. Verb.Dt.Ges.Inn.Med. 89, 721-723, 1983. 27. Schernthaner G, Kostner GM, Dieplinger H, Prager R, Mühlhauser I: Apolipoproteins (AI, AII, B), lipoprotein (a) and lecithin cholesterol – acetyltransferase activity in diabetes mellitus. Atherosclerosis 49, 277–293, 1983. 28. Prager R, Schernthaner G : Insulin receptor binding to monocytes, insulin secretion and glucose tolerance following metformin treatment . Results of a double blind cross over study in type II diabetics. Diabetes 32, 1083-1086, 1983. 29. Ertl L, Prager R : Gesichts - und Mediastinalemphysem im Anschluss an Zahnextraktion. Österr. Z. Stomatol. SO, 340-342. 1983. 30. Graf H, Stummvoll HK, Prager R, Luger A, Kovarik J : Protein binding and dialysate concentration of aluminum - the major determinants of aluminum kinetics during hemodialysis. Chemical Toxicology and Clinical Chemistry of Metals. S.S. Brown, J. Savory Eds. Academic Press, London - New York, 357-360, 1983. 31. Luger A, Graf H, Prager R, Stummvoll HK : Die kontinuierliche arteriovenöse Hämofiltration als Therapie der akuten Niereninsuffizienz . Wr. Klin. Wschr. 96,1-4 1984. 32. Prager R, Schernthaner G, Kovarik J, Cichini G, Klaushofer K, Willvonseder R : Primary hyperparathyreoidism is associated with decreased insulin receptor binding and glucose intolerance. Calcif. Tissue Int. 36, 253-258, 1984. 33. Luger A, Graf H, Prager R, Stummvoll HK : Alterations in the renin - angiotensin -aldosterone system in the critically Ill . Horm. metabol. Res. 16, 213-214, 1984. 34. Schernthaner G, Prager R : Insulinrezeptor - und Postrezeptorstörungen : Bedeutung für Entstehung und Therapie von Kohlenhydratstoffwechselstörungen. Acta med. Austriaca 1, 70-77, 1984. 35. Schernthaner G, Prager R, Weissel M, Höfer R : Decreased insulin receptor binding in hyperthyreoidism. Klin. Wschr. 62 : 1074-1080, 1984. 36. Schernthaner G, Prager R, Punzengruber C, Luger A : Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28, 138-142, 1985. 37. Graf H, Prager R, Kovarik J, Luger A, Schernthaner G, Pinggera WF: Glucose metabolism and insulin sensitivity in patients on chronic hemodialysis . Metabolism 34 : 974-977, 1985. 38. Prager R, Schernthaner G, Graf H, Chichini G, Luger A : Influence of acute experimental hypercalcemia on peripheral insulin sensitivity in healthy subjects . Diabetes Research 3 : 199 – 20, 1986. 39. Prager R, Schernthaner G, Graf H : Effect of metformin treatment on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete & Metabolisme 12 : 346-350, 1986. 40. Prager R, Wallace P, Olefsky JM : In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. J. Clin. Invest. 7S: 472-481, 1986. 41. Baron A, Wallace P, Brechtel G, Prager R: Somatostatin does not increase Insulin-stimulated Glucose Uptake in Humans. Diabetes 36, 33–36, 1987. 42. Prager R, Wallace P, Olefsky JM : Hyperinsulinemia Does not compensate for peripheral Insulin Resistance in Obesity. Diabetes 36, 327–334, 1987. 43. Bergman RN, Prager R, Volund A, Olefsky JM : Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic Glucose clamp. J. Clin. Invest. 79, 790-800, 1987. 44. Prager R, Wallace P, Olefsky JM : Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes 36, 607-61, 1987. 45. Prager R : Receptor and postreceptor abnormalities in diabetes. In Clinical Immunology International Congress Series 718 Ed. Pruzanski W. Seligmann M. Excerpta Medica, Amsterdam - New York Oxford, 35-41, 1987. Arbeiten nach der Habilitation:
46. Bratusch Marrain P, Prager R, Kacerovsky-Bielesz G, lrsigler K, Borkenstein M, Biesenbach G, Kitzler P, Hopferwieser Th, Pretsch I, Sulzer M : Stand der Betreuung der Typ - I -Diabetiker in Österreich. Wien.Klin.Wschr. 100, 442-449,1988. 47. Klauser R, Schernthaner G, Prager R : Mixtures of human intermediate and human regular insulin in type I diabetic patients. Diabetes Research and Clinical Practice 5,185-190, 1988. 48. Prager R : Pathogenese und Therapie des Diabetes mellitus Typ I und Typ II. 49. Baron AD, Kolterman OG, Prager R, Freidenberg GR, Henry RR, Garvey WT, Olefsky JM : Mechanisms of insulin resistance in obese and type II diabetic subjects. In Diabetes Mellitus : Pathophysiology and Therapy. Ed. Creutzfeld W. And Lefebre P., Springer Verlag Berlin-Heidelberg-New York-London-Paris-Tokyo, 107-126, 1988. 50. Schnack C, Prager R, Winkler J, Klauser R, Schernthaner G : Effects of 8 Wk a- Glucosidase inhibition on metabolic control, c - peptid secretion, hepatic glucose output and peripheral insulin sensitivity in poorly controlled type II Diabetic patients. Diabetes Care 12, 537-543, 1989. 51. Prager R : Therapie der Hyperlipidämie mit HMG - CoA – Reduktasehemmern. Wien.med. Wschr. 139, Suppl. 105, 17-20,1989. 52. Klauser R, Mühlbacher F, Gnant M, Prager R, Brauner E, Pacini G, Kovarik J : Pancreatic transplantation with venous portal drainage. Lancet, 988, 1989. 53. Klauser R, Prager R, Watschinger B, Schernthaner G : Metabolic effects of biosynthetic human proinsulin in type II diabetes mellitus. Europ. J. Clin. Invest. 19, 466-479, 1989. 54. Prager R, Schernthaner G, Niederle B, Roka R: Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyreoidism before and after surgery. Calc. Tissue Intern 46: 1-4, 1990. 55. Kueenburg H, Brunnbauer M, Watzinger U, Winter F. Müller MM, Graf H., Prager R. : Die Wertigkeit von Fruktosamin bei Hämodialysepatienten. Wien. Klin. Wschr.: 102, Suppl. 180, 11-13. 1990. 56. Brunnbauer M, Kuenburg E, Winter F, Müller MM, Prager R : Tageszeitliche Schwankungen von Fruktosamin bei Patienten mit Typ - II Diabetes mellitus . Wien. Klin. Wschr. 102, Suppl. ISO, 72-73, 1990. 57. Hartter E, Svoboda T, Leil B, Schuller M, Ludvik B, Woluzczuk W, Prager R : Reduced islet - amyloid polypeptide in insulin - dependent diabetes mellitus. Lancet , 854, 1990. 58. Prager R : Warum das Insulin beim Typ - II Diabetiker nicht richtig zur Wirkung 59. Klauser R, Speiser P, Gisinger C, Schernthaner G, Prager R : Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. J. Cardiovasc. Pharmacol. 15, Suppl. 1, 93-96,1990. 60. Mühlbacher F, Gnant MFX, Auinger M, Steininger R, Klauser R, Prager R, Karnel F : Pancreatic venous drainage to the portal vein: A new method in human pancreas transplantation. Proceedings 22, 636-637, 1990. 61. Luger A, Prager R, Gaube S, Graf H, Klauser R, Schernthaner G : Decreased peripheral insulin sensitivity in acromegalic patients. Exp. Clin. Endocrinol. 95, 339-343, 1990. 62. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kueenburg E, Brunnbauer M, Woloszczuk W, Prager R : Basal and stimulated plasma levels of pancreatic amylin indicate its co - secretion with insulin in humans. Diabetologia 34 ,52-54,1991. 63. Sachs G, Spiess K, Moser G, Prager R, Kunz A, Schernthaner G : Glykosiliertes Hämoglobin und Glukose - Selbstmonitoring ( Compliance ) bei depressiven und nicht depressiven Typ 1- Diabetikern. Psychother., Psychosom. med. Psychol. 41, 306-312, 1991. 64. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C Kueenburg E, Schernthaner G : Metabolic Effects of Isradipine vs. Hydrochlorothiazide in Diabetes mellitus. Hypertension 1, 15-21, 1991. 65. Prager R, Ludvik B, Hartter E : Die Rolle von Amylin in der Pathogenese des Typ- II-Diabetes mellitus. Acta Medica Austriaca IS, 61-62, 1991. 66. Mihaljevic R, Bratusch-Marrain P, Hoffmann H, Langmayr N, Prager R : Patientengerechte Insulinapplikation bei Typ II- Diabetikern. Therapiewoche Österreich 6, 7, 487-496, 1991. 67. Klauser R, Prager R, Schernthaner G, Olefsky JM : Contribution of postprandial insulin and glucose to glucose disposal in normal and insulin-resistant obese subjects. J. Clin. Endocrin. Metab. 73, 258-264, 1991. 68. Watschinger B, Brunner Ch, Schnack Ch, Prager R, Weissel M, Burghuber OC : Left and right ventricular function in normotensive type I diabetic patients. In: Cardionephrology , Eds.: M.Timio, V. Wizemann. Wichtig Editore, ISBN 88-85053-92-0, p. 115-118, 1991. 69. Ludvik B, Lell B, Hartter E, Schnack C, Prager R: Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes mellitus. Diabetes 40,1615-1619,1991. 70. Ludvik B, Kuenburg E, Brunnbauer M, Schernthaner G, Prager R : The Effects of Ramipril on Glucose Tolerance, Insulin Secretion, and insulin Sensitivity in patients with Hypertension. J. of Cardiovasc. Pharm. 18, Suppl. 2, 157-159, 1991. 71. Virgolini I, Angelberger P, Banyai M, Knöbl P, Pantev T, Neuhold N, Prager R, Sinzinger H: 123 I- tyrosine- ( A 14 )-insulin: preparation and preliminary clinical studies. Wien.klin. Wschr. 103 , 657-60, 1991. 72. Ludvik B, Kautzky-Willer A, Prager R : Epidemiologie, Ätiologie und neue therapeutische Konzepte bei Adipositas. Therapiewoche Österreich,7,10-16,1992. 73. Kautzky-Willer A, Pacini G, Niederle B, Schernthaner G, Prager R: Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyreoidism before and after surgery. Clinical Endocrinology 37,147-155,1992. 74. Niederle B, Stamm L, Längle F, Schubert E, Woluszczuk W, Prager R : Primary hyperparathyreoidism in Austria: Results of an 8 year prospective study. World J. Surgery 16, 777-783, 1992. 75. Kautzky-Willer A, Pacini G, Ludvik B, Schernthaner G, Prager R: B cell hypersecretion and not reduced hepatic extraction causes hyperinsulinemia in obese nondiabetic subjects. Metabolism 41:1304-1312,1992. 76. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R : Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36:84-87,1993. 77. Prager R : Amylin und Typ II-Diabetes. Diabetes und Stoffwechsel 2,40- 78. Kautzky-Willer A, Niederle B, Schernthaner G, Prager R: Diabetes mellitus und Kohlenhydratstoffwechsel beim primaren Hyperparathyreoidismus. Wien. Klin. Wschr. 105/6, 158-162,1993. 79. Watschinger B, Brunner Ch, Wagner A., Schnack Ch, Prager R, Weissel M, Burghuber OC : Left ventricular diastolic Impaired in type I diabetic patients with microalbuminuria. Nephron 63, 145-151, 1993. 80. Prager R, Streli C. Prager R : Diabetes und Sport Wr. Med. Wschr. 143, 9-12, 81. Kautzky-Willer A, Pacini G, Weissel M, Capek M, Ludvik P, Prager R: Elevated hepatic insulin extraction in essential hypertension. Hypertension 21: 646- 653,1993. 82. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, Müller M: Thrombogenic factors are related to urinary albumin excretion rate in type I (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 1045-1050,1993. 83. Kautzky-Willer A, Endler AT, Streli C, Graf H, Prager R: Glycated hemoglobin in hemodialysis patients with and without erythropoietin substitution: a method comparison. Klin. Lab. 39,1-3,1993, S.1046. 84. Kautzky-Willer A, Capek M, Weissel M, Ludvik B, Prager R, Pacini G: Insulin sensitivity, secretion and hepatic extraction in untreated hypertensive patients. In: Current Topics in Diabetes research (Editors: F.Belfiore.R. N. Bergman, G. M. Molinatti ). Karger, Basel 1993, 250-253. 85. Sachs G, Spiess K, Moser G, Kautzky-Willer A, Lugner A, Pietschmann P, Schernthaner G, Prager R : Hormonal and blood glucose responsiveness as an indicator of specific emotional arousal in Type I diabetics. J. Psychosom. Res. 37, 831-842, 1993. 86. Kautzky-Willer A, Tomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhäusl W, Prager R: Role of islet amyloid polypeptide secretion in insulin resistant humans. Diabetologia 37,188-194,1994. 87. Schnack Ch, Capek M, Banyai M, Kautzky-Willer A, Prager R , Schernthaner G: Long term treatment with nifedipine reduces urinary albumin excretin rate in treatment in normotensive type-1 diabetic patients with microalbuminuria. Acta Diabetologica Latina 31, 14-18,1994. 88. Schnack Ch, Pietschmann P, Knöbl P, Schuller E, Prager R, Schernthaner G : Apolipoprotein ( a ) levels and artherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus . Nephron 66, 273-277, 1994. 89. Knöbl P, Pietschmann P, Schnack C, Prager R, Schernthaner G: Apolipoprotein (a) levels in patients with type I diabetes mellitus are unrelated to metabolic control or vascular disease. Wien.klin.Wschr.: 106, 728-732, 1994. 90. Ludvik B, Lell B, Hartter E, Stifter S, Graf H, Prager R: Increased of circulating amylin in patients with chronic renal failure have no effect on insulin secretion. J.Clin.Invest. 94, 2045-2050, 1994. 91. Spiess K, Sachs G, Frischenschlager O, Moser G, Schernthaner G, Prager R: Zur phasenspezifischen Funktion der Vorbeugung beim Typ I Diabetes- Patienten nach Krankheitsausbruch. Z. Psychosom. Med Psychoanal. 40, 52-67,1994. 92. Spiess K, Sachs G, Moser G, Pietschmann P, Schernthaner G, Prager R: Psychological moderator variables and metabolic control in recent onset type I diabetic patients – a two year longitudinal study. J Psychosom. Res , 38, 249 - 258, 1994. 93. Capek M, Schnack C, Ludvik B, Kautzky-Willer A, Banyai M, Prager R: Effect of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria. Clin. Investig. 72, 961-966,1994. 94. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T: Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb. Haemostas. 71, 692-697, 1994. 95. Prager R: Diabetes state of the art. Ungelöste Probleme und Zukunftsperspektiven. Hausarzt 5, 6-8, 1994. 96. Prager R: Stufentherapie des Diabetes mellitus Typ II. Forum Dr. Med. 1842- 97. Pacini G, Tomaseth K, Kautzky-Willer A, Prager R: An integrated mathematical models of islet amyloid polypeptide dynamics. Modeling and control in Biomedical Systems. B.W. Patterson (Ed.) Omnipress, Madison WI, 377-378, 1994. 98. Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R: Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney International 47, 200-206, 1995. 99. Griesmacher A, Kindhauser M, Andert S, Schreiner W, Toma C,Knöbl P, Pietschmann P, Prager R, Schnack C, Schernthaner G, Müller MM : Enhanced serum levels of thiobarbituric-acid reactive substances in diabetes mellitus. Am. J. Med. 98, 469 – 475, 1995. 100. Prager R: Adipositas: Physiologie und Behandlungsmöglichkeiten. Acta med. 101. Geyer G, Haidinger G, Francesconi M, Langmayr N, Prager R, Schoberberger R, Toplak H, von Kalkreuth G, Kunze M: Der Einfluss von Dexfenfluramin auf Essverhalten und Körpergewicht von Adiposenergebnissen einer Anwendungsstudie von Isomeride in österreichischen Artzpraxen. Acta med. Austriaca 22, 95-109, 1995. 102. Spiess K, Sachs P, Pietschmann P, Prager R: Program to reduce onset distress in unselected type I diabetic patients : effects on psychological variables and metabolic control. Europ. J. Endocrinol. 132, 580-586, 1995. 103. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G: An integrated mathematical model to assess B-cell activity during the oral glucose test. Am.J.of Physiol.270, E522-E531, 1996. 104. Kotzmann H, Linkesch M, Ludvik B, Clodi M, Luger A, Schernthaner G, Prager R, Klauser R: Effect of danazole-induced hyperglucagonemia on glucose tolerance. Europ.J.of Clini.lnvest. 25, 942-947,1996. 105. Kautzky-Willer A, Tomaseth K, Clodi M, Ludvik B, Waldhäusl W, Prager R, Pacini G: Dexamethasone treatment enhances beta cell activity in healthy humans. Metabolism 45, 486-491, 1996. 106. Bamas U, Schmidt A, Illievich A, Kiener HP, Rabensteiner D, Kaider A, Prager R, Abrahamian H, lrsigler K, Mayer G: Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control. Diabetologia 40, 327-331, 1997. 107. Tomaseth K, Pacini G, Clodi M, Kautzky-Willer A, Nolan JJ, Prager R, Olefsky JM, Ludvik B: Amylin release during oral glucose tolerance test. Diabetic Medicine 14, Suppl 2, 29-34,1997. 108. Ludvik B, Kautzky-Willer A, Prager R, Tomaseth K, Pacini G.: Amylin, History and overview. Diabetic Medicine 14, Suppl. 2, 9-13,1997. 109. Kautzky-Willer A, Tomaseth K, Ludvik B, Nowotny P, Rabensteiner D, Waldhäusl W, Pacini G, Prager R: Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes 46, 607-614, 1997. 110. Kautzky-Willer A, Prager R, Waldhäusl W, Pacini G, Tomaseth K, Wagner OF, Ulm M , Streli C, Ludvik B: Pronounced insulin resistance and inadequate 6 cell secretion characterize lean gestational diabetes mellitus during and after pregnancy. Diabetes Care 20, 1619-1623,1997. 111. Clodi M, Thomaseth K, Pacini G, Hermann A, Kautzky-Willer A, Waldhäusl W, Ludvik B, Prager R: Distribution and kinetics of amylin in humans. Am.J.Physiol. 274, E 903-908. 1998. 112. Fliser D, Pacini G, Engelreiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and Hyperinsulinemia in Patients with incipient renal disease. Kidney Intern 53, 1343-1347, 1998. 113. Rabensteiner D, Abrahamian H, Irsigler K, Hermann K, Kiener H, Mayer G, Kaider A, Prager R: ACE Gene Polymorphismus and Proliferative Retinopathy in type 1 Diabetes. Diabetes Care 22, 1530-1535, 1999. 114. Tura A, Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G: Modelling beta cell secretion and kinetics of proinsulin during an oral glucose test.Health Sciences simulation 2000, Anderson JK and Katzper M. (Eds.), SCS Press, San Diego, USA 103-108, 2000. 115. Riedl M, Ludvik B, Pacini G, Clodi M, Kotzmann H, Wagner O, Kautzky-Willer A, Prager R, Luger A: The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. Europ. J.Clini.Invest. 30, 771-778, 2000. 116. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, Prager R und Waldhäusl W: Increased plasma leptin in gestational diabetes. Diabetologia 44, 164-172, 2001. 117. Ludvik B, Mahdjoobian K, Waldhäusl W, Hofer A, Prager R, Kautzky-Willer A, Pacini G: The Effect of Ipomoea batatas (Caiapo) on Glucose Metabolism and Serum Cholesterol in Patients with Type 2 Diabetes. A randomized study. Diabetes Care 25, 239-240, 2002. 118. Abrahamian H, Prager R: Senkung der kardiovasculären Morbidität und Mortalität durch antihypertensive Kombinationstherapie bei Patienten mit Typ 2-Diabetes mellitus. Wien.Med.Wochenschr 159, 210-214, 2002. 119. Georg P, Kautzky-Willer A, Mahjoobian K, Hofer A, Prager R, Pacini G, Ludvik B: Influence of Metabolic Control on Splanchnic Glucose Uptake, Insulin Sensitivity, and the Time Required for Glucose Absorption in Patients with Type 1 Diabetes. Diabetes Care 25, 2042-2047, 2002. 120. Abrahamian H, Schueller A, Mauler H, Prager R, Irsigler K: Transfer of knowledge from the specialist to the generalist by videoconferencing: effect on diabetes care. J Telemed Telecare 8, 350-355, 2002. 121. Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR, Wolf H, Prager R, Eibl MM: Acute-phase response and immunological markers in morbid obese patients following adjustable gastric banding. Int.J.Obes.Relat.Metab.Disord. 27, 355-361, 2003. 122. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K: Basal and dynamic proinsulin-insulin relationship to assess ß-cell function during OGTT in metabolic disorders. Am.J.Physiol. 285, E 155-162, 2003. 123. Ludvik B, Tomaseth K, Nolan Jj, Clodi M, Prager R, Pacini G: Inverse relation between amylin and glucagons secretion in healthy and diabetic human subjects. Europ.J.Clin. Invest. 33, 316-322, 2003. 124. Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mähr B, Dunky A, Rosen HR, Köller U, Prager R: Effect of Gastric Banding on Aminoterminal Pro-brain Natriuretic Peptide in the Morbidly Obese. Obesity Research 11, 695-698, 2003. 125. Ludvik B, Waldhäusl W, Prager R, Kautzky-Willer A, Pacini G: Mode of Action of Ipomoea Batatas (Caiapo) in Type 2 Diabetic Patients. Metabolism 52, 875-880, 2003. 126. Hanusch-Enserer U, Cauza E, Spak M, Endler G, Dunky A, Tura A, Wagner O, Rosen HR, Pacini G, Prager R: Improvement of Insulin Resistance and Early Atherosclerosis in Patients after Gastric Banding. Obesity Research 12, 284-291, 2004. 127. Kästenbauer T, Irsigler P, Sauseng S, Grimm A, Prager R: The prevalence of symptoms of sensorimotor and autonomic neuropathy in Type 1 and Type 2 diabetic subjects. J Diabetes Complications 18, 27-31, 2004. 128. Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R: Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Technol Ther. 6, 31-37, 2004. 129. Hanusch-Enserer U, Cauza E, Brabant G, Dunky A, Rosen H, Pacini G, Tuchler H, Prager R, Roden M: Plasma ghrelin in obesity before and after weight loss after laparascopical adjustable gastric banding: J.Clin.Endocrinol.Metab. 89, 3352-3358, 2004. 130. Hanusch-Enserer U, Enserer C, Rosen HR, Prager R: Indikation zur operativen Adipositastherapie. Acta Med Austriaca 31, 125-129, 2004. 131. Stadler M, Prager R: Typ 2 Diabetes mellitus-Screening und Prävention. Acta 132. Kautzky-Willer A, Lechleitner M, Pieber TR, Prager R, Roden M, Wascher TC, Weitgasser R: Therapie mit oralen Antidiabetika. Acta Med Austriaca 31, 162-163, 2004. 133. Kautzky-Willer A, Lechleitner M, Pieber TR, Prager R, Roden M, Wascher TC, Weitgasser R: Insulintherapie. Acta Med Austriaca 31, 164-165, 2004. 134. Edlinger R, Auinger M, Prager R: Diabetische Nephropathie. Acta Med 135. Hermann-Arnhof KM, Hanusch-Enserer U, Kästenbauer T, Publig T, Dunky A, Rosen HR, Prager R, Koller U: N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem 51, 138-143, 2005. 136. Engl J, Hanusch-Enserer U, Prager R, Patsch JR, Ebenbichler C: Das Metabolische Syndrom: Auswirkungen einer ausgeprägten Gewichtsabnahme mittels chirurgischer Intervention. Wien.Klin.Wschr.117, 243-254, 2005. 137. Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, Wagner O, Georg P, Prager R, Kostner K, Dunky A, Haber P: The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arch Phys Med Rehabil 86, 1527-1533, 2005. 138. Funk M, Endler G, Exner M, Marculescu R, Endler L, Abrahamian H, Mauler H, Grimm A, Raith M, Mannhalter C, Prager R, Irsigler K, Wagner O: PAI 1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wschr 117/19-20, 707-710, 2005. 139. Prager R: Ezetrol® in der Praxis. J Kardiol 12 (Suppl B), 11-12, 2005. 140. Auinger M, Edlinger R, Prager R: Perionealdialyse bei Patienten mit diabetischer Nephropathie. Wien Klin Wschr 117/6, 1-6, 2005. 141. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R: Efficacy and Safety of Insulin Glulisine in Patients with Type 1 Diabetes. Horm Metab Res 2005; 37: 702-707, 2005. 142. .Stadler M, Anderwald Ch, Karer T, Tura A, Kästenbauer T, Auinger M, Bieglmayer Ch, Wagner O, Kronenberg F, Nowotny P, Pacini G, Prager R: Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation. Diabetes Care 29: 1031-1038, 2006. 143. Kautzky-Willer A, Tura A, Winzer C, Wagner O.F, Ludvik B, Hanusch-Enserer U, Prager R, Pacini G: Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. Diabetes, Obesity and Metabolism Volume 8, Issue 5,Sep 2006. 144. Kästenbauer T, Wassermann J, Krippl E, Prager R, Irsigler K: Measurement of the walking duration with therapeutic shoes in neuropathic diabetic patients by a novel device (Show-me). Diab Care 29/6,1456, 2006. 145. Stadler M, Auinger M, Anderwald C, Kästenbauer T, Kramar R, Feinböck C, Irsigler K, Kronbenberg F, Prager R: Long-Term Mortality and Incidence of Renal Dialysis and Transplantation in Type 1 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism 91(10):3814–3820, 2006. 146. Kollerits B, Auinger M, Reisig V, Kästenbauer T, Lingenhel A, Irsigler K, Prager R, Kronenberg F: Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diab Care 29/7, 1661-63, July 2006. 147. Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, Rumpold H, Gerdov M, Mannhalter C, Prager R, Irisgler K, Wagner O.F: Association of Low-Grade Inflammation with Nephropathy in Type 2 Diabetic Patients: Role of Elevated CRP-Levels and 2 Different Gene-Polymorphisms of Proinflammatory Cytokines. Exp Clin Endocrnol Diabetes 2007 ; 115 : 38-41, 2007. 148. Hanusch-Enserer U, Ghatei Mohammed A., Cuaza E, Bloom Steven R., Prager R, Roden M: Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgery. Wien Klin Wochenschr 119/9-10: 291-296, 2007. 149. M. Anderwald-Stadler, Krebs M, Promintzer M, Mandl M, Bischof MG, Nowotny P, Kästenbauer T, Luger A, Prager R, Anderwald C: Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistanz humans. Am J Physiol Endocrinol Metab. 293(5):E1393-8, 2007. 150. Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, Karnieli E, Assalia A, Prager R, Prager G: Improvement in glycemic control by gastric electrical stimulation (TANTALUS(TM)) in overweight subjects with type 2 diabetes. Surg Endosc. 23(9):1955-60, 2008. 151. Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Prager R, Abrahamian H. Riedl M, Pacher R, Luger A, Clodi M: NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J. 29(18):2259-64, 2008. 152. Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, Schillinger M, Roden M, Huber K: Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 30(12):1516-24, 2009.
Originalarbeiten als kooperierendes Zentrum:

1.
Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 156(4):623-32, 2008. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C. Linn T. Once-daily basal insulin glargine versus thrice-daily prandiale insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371(9618):1073-84, 2008. Erratum in: Lancet 372(9640):718, 2008. Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab. 10(5):387-99, 2008.
Buch und Buchbeiträge:

1.
R. Prager: Diabetesmanagement mit Insulinanaloga, UNI-MED Science, 1. Aufl. 2008. [ISBN 978-3-89599-919-2] M. Anderwald-Stadler, R. Prager: “Typ 2 Diabetes Mellitus”, Buchbeitrag für “Ernährungsmedizin” (Hrsg. Univ.-Prof. Dr. Kurt Widhalm), Verlagshaus der Ärzte, 3. Aufl. 2009. [ISBN 978-3-902552-44-0]

Source: http://www.drprager.at/dl/presse/drprager_publikationen.pdf